ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
Turner, N BalmaƱa, J Fasching, P Hurvitz, S Rugo, H Telli, M Visco, F Wardley, Andrew M Yang, X Lokker, NA
Turner, N
BalmaƱa, J
Fasching, P
Hurvitz, S
Rugo, H
Telli, M
Visco, F
Wardley, Andrew M
Yang, X
Lokker, NA
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer 2016, 76 (4 Supplement):OT1-03-17 Cancer Research